[ad_1]
Nick Wykeman, CFO of Allergy Therapeutics PLC (LON: AGY), talks to Andrew Scott, of London's pro-active, updating their trading for the year to end of June 2019.
According to him, the net revenue for the year should reach 73.7 million pounds, up 8% over last year, while the cash at the end of June 's. amounted to £ 27.4 million.
This means that the group has the funds to fully fund the Phase III clinical trial of its new inoculation against grbad allergy in abbreviated form starting next fall.
Source link
